{"id":19094,"date":"2024-12-20T22:08:46","date_gmt":"2024-12-20T14:08:46","guid":{"rendered":"https:\/\/flcube.com\/?p=19094"},"modified":"2024-12-20T22:08:47","modified_gmt":"2024-12-20T14:08:47","slug":"guardant-health-and-boehringer-ingelheim-join-forces-to-develop-guardant360-cdx-for-zongertinib-companion-diagnostic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19094","title":{"rendered":"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic"},"content":{"rendered":"\n

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH<\/a>) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.<\/p>\n\n\n\n

Zongertinib: A Potential Treatment for HER2 Mutation Positive NSCLC Patients<\/strong>
Zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) developed by BI, is under development specifically to target NSCLC patients with HER2 mutations. This targeted approach to treatment has the potential to significantly improve patient outcomes by addressing the underlying genetic mutations that drive the disease.<\/p>\n\n\n\n

Guardant360 CDx: A Comprehensive Liquid Biopsy for Advanced Solid Tumors<\/strong>
Guardant360 CDx is the first FDA-approved comprehensive liquid biopsy designed for all advanced solid tumors. Its approval as a companion diagnostic (CDx) for multiple targeted therapies in NSCLC further solidifies its role in personalized medicine. The collaboration between Guardant Health and Boehringer Ingelheim is expected to leverage the strengths of both companies to advance this innovative diagnostic tool, potentially leading to more effective treatment strategies for patients.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with…<\/p>\n","protected":false},"author":1,"featured_media":19096,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[587,390,2862,2863],"class_list":["post-19094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bi","tag-boehringer-ingelheim","tag-guardant-health","tag-nasdaq-gh"],"yoast_head":"\nGuardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19094\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic\" \/>\n<meta property=\"og:description\" content=\"US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19094\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T14:08:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-20T14:08:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic\",\"datePublished\":\"2024-12-20T14:08:46+00:00\",\"dateModified\":\"2024-12-20T14:08:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2004-1.png\",\"keywords\":[\"BI\",\"Boehringer Ingelheim\",\"Guardant Health\",\"NASDAQ: GH\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19094#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19094\",\"name\":\"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2004-1.png\",\"datePublished\":\"2024-12-20T14:08:46+00:00\",\"dateModified\":\"2024-12-20T14:08:47+00:00\",\"description\":\"US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19094\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2004-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2004-1.png\",\"width\":1080,\"height\":608,\"caption\":\"Guardant Health and Boehr Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19094#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic - Insight, China's Pharmaceutical Industry","description":"US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19094","og_locale":"en_US","og_type":"article","og_title":"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic","og_description":"US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.","og_url":"https:\/\/flcube.com\/?p=19094","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-20T14:08:46+00:00","article_modified_time":"2024-12-20T14:08:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19094#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19094"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic","datePublished":"2024-12-20T14:08:46+00:00","dateModified":"2024-12-20T14:08:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19094"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19094#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png","keywords":["BI","Boehringer Ingelheim","Guardant Health","NASDAQ: GH"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19094#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19094","url":"https:\/\/flcube.com\/?p=19094","name":"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19094#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19094#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png","datePublished":"2024-12-20T14:08:46+00:00","dateModified":"2024-12-20T14:08:47+00:00","description":"US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer (NSCLC) patients with HER2 mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19094#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19094"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19094#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png","width":1080,"height":608,"caption":"Guardant Health and Boehr Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19094#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2004-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19094"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19094\/revisions"}],"predecessor-version":[{"id":19097,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19094\/revisions\/19097"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19096"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}